Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
81.71
-0.11 (-0.13%)
At close: Jun 13, 2025, 4:00 PM
81.90
+0.19 (0.23%)
After-hours: Jun 13, 2025, 7:59 PM EDT
Merck & Co. Revenue
Merck & Co. had revenue of $15.53B in the quarter ending March 31, 2025, a decrease of -1.56%. This brings the company's revenue in the last twelve months to $63.92B, up 4.10% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$63.92B
Revenue Growth
+4.10%
P/S Ratio
3.23
Revenue / Employee
$852,293
Employees
75,000
Market Cap
205.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
| Thermo Fisher Scientific | 42.90B |
MRK News
- 1 day ago - Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda - Investopedia
- 1 day ago - FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent - Business Wire
- 2 days ago - Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs - Business Wire
- 2 days ago - Exclusive: Kennedy's new vaccine adviser was expert witness against Merck vaccine - Reuters
- 2 days ago - Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025 - Business Wire
- 2 days ago - Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate - Business Wire
- 4 days ago - Merck: Best Case For Option Collars We'll Ever See - Seeking Alpha
- 4 days ago - Drug pricing reform talks with US government lack clarity, industry executives say - Reuters